Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis.
The development of oxaprozin provided an opportunity to evaluate the control of inflammation in rheumatoid arthritis by a drug that can be administered once daily. A double-blind 12-week evaluation suggested comparable efficacy between 1,200 mg oxaprozin given as a single daily dose and 3,900 mg ASA given in 4 equally divided doses. A lower incidence of side effects was noted in the oxaprozin group. An open 6-month study substantiated the efficacy and safety of oxaprozin.